Skip to main content

Table 1 Relationship between clinical characteristics and PD-L1 and PD-1 expression in intrahepatic cholangiocarcinoma

From: Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients

  n PD-L1 expression PD-1 expression
Cancerous cell (+) p value Stromal cells (+) p value Lymphocyte (+) p value
Total number 69 8 (11.6%)   35 (50.7%)   21 (30.4%)  
Age, years; median (range) 60 (34–81) 63 (46–79) 0.499 63
(43–81)
0.025 60 (50–76) 0.984
Gender    0.266   0.264   0.006
 Male 40 3 (7.5%)   18 (45%)   7 (17.5%)  
 Female 29 5 (17.2%)   17 (58.6%)   14 (48.3%)  
HBV infection 28   0.337   0.555   0.781
 HBsAg, positive   5 (17.9%)   13 (46.4%)   8 (28.6)  
 HBsAg, negative   3 (7.3%)   22 (53.7%)   13 (31.7%)  
CA19-9 > 39.9U/ml 38   0.494   0.726   0.177
 CA19-9, positive   3 (7.9%)   20 (52.6%)   9 (23.7%)  
 CA19-9, negative   5 (16.1%)   15 (48.4%)   13 (41.9%)  
TB > 20.5umol/L 13   1.0   0.803   0.33
 TB, positive   2 (15.4%)   7 (53.8%)   2 (15.4%)  
 TB, negative   6 (10.7%)   28 (50%)   19 (33.9%)  
DB > 6.8umol/L 10   0.865   0.187   0.974
 DB, positive   1 (10%)   7 (70%)   3 (30%)  
 DB, negative   7 (11.9%)   28 (47.5%)   18 (30.5%)  
ALT > 40U/L 16   0.644   0.184   0.916
 ALT, positive   3 (18.8%)   11 (68.8%)   5 (31.3%)  
 ALT, negative   5 (9.4%)   24 (45.3%)   16 (30.2%)  
AST > 40U/L 18   0.724   0.305   0.776
 AST, positive   3 (16.7%)   11 (61.1%)   5 (27.8%)  
 AST, negative   5 (9.8%)   24 (47.1%)   16 (31.4%)  
γ-GT > 35U/L 48   0.957   0.056   0.824
 γ-GT, positive   5 (10.4%)   28 (58.3%)   15 (31.3%)  
 γ-GT, negative   3 (14.3%)   7 (33.3%)   6 (28.6%)  
  1. HBV hepatitis B virus, HBsAg hepatitis B surface antigen, CA19-9 Carbohydrate antigen 19–9, TB total bilirubin, DB direct bilirubin, ALT alanine transaminase, AST aspartate transaminase, γ-GT gamma-glutamyl transpeptidase